Oncology Brothers: Practice-Changing Cancer Discussions Leukemia ASH 2024 Highlights - Menin Inhibitors, CPX 351 vs 7+3, Venetoclax Based Regimens
Dec 19, 2024
Dr. Uma Borate, a leukemia treatment expert from The Ohio State University, joins the hosts for an insightful discussion on breakthroughs from ASH 2024. They delve into the promising KOMET 007 study on the Menin inhibitor Ziftomenib, noting its effectiveness for patients with specific genetic mutations. The conversation shifts to the comparison between CPX351 and traditional 7+3 induction therapies, revealing key insights about response rates. Additionally, they explore the role of Venetoclax in treating patients without actionable mutations, emphasizing NGS testing's vital role in targeted therapies.
AI Snips
Chapters
Transcript
Episode notes
Menin Inhibitors Show High Frontline Response
- Menin inhibitors like Ziftomenib show very high complete remission rates in frontline AML with NPM1 mutations or KMT2A rearrangements.
- Their toxicity profile is manageable, with differentiation syndrome present but not severe in frontline combinations.
Early Treat Differentiation Syndrome
- Treat differentiation syndrome from menin inhibitors early with steroids and hydroxyurea.
- Monitor patients closely around week two of therapy when differentiation syndrome commonly appears.
NGS Testing Vital for AML Mutations
- NGS testing is critical to identify AML patients with targetable mutations like NPM1 and KMT2A rearrangements.
- These mutations are stable at diagnosis and relapse, guiding therapy choices throughout disease course.